Optimization of BMD measurements to identify high risk groups for treatment - A test analysis

Journal of Bone and Mineral Research

Volumn 19, Issue 6, 2004, Pages 906-913

  Johansson, Helena ^a   Oden, Anders ^a   Johnell, Olof ^b   Jonsson, Bengt ^c   De Laet, Chris ^d   Oglesby, Alan ^e   McCloskey, Eugene V ^f   Kayan, Karthik ^f   Jalava, Tarja ^g   Kanis, John A ^f  

^a Malmo General Hospital ^*

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e ELI LILLY AND COMPANY   (United States)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

^g Oy Leiras Finland Ab   (Finland)

Author keywords

BMD tests; Fracture possibility; Intervention threshold

Indexed keywords

CORTICOSTEROID;

AGED; ARTICLE; BODY MASS; BONE DENSITY; CLINICAL FEATURE; CONTROLLED STUDY; DEATH; FEMALE; FRACTURE; HIGH RISK POPULATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; METHODOLOGY; OSTEOPOROSIS; POISSON DISTRIBUTION; PROBABILITY; RISK FACTOR; SEX RATIO; TREATMENT OUTCOME; UNITED KINGDOM; RADIODENSITOMETRY;

AGED; BONE DENSITY; DENSITOMETRY, X-RAY; FEMALE; HUMANS; RISK FACTORS;

EID: 8444224686     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2004.19.6.906     Document Type: Article

References (33)

1. Royal College of Physicians 1999 Osteoporosis: Clinical Guidelines for Prevention and Treatment. Royal College of Physicians: London, UK.
2. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D on behalf of the European Foundation for Osteoporosis and Bone Disease 1997 Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 7:390-406.
3. National Osteoporosis Foundation 1998 Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporos Int 8(Suppl 4):1-88.
4. European Commission 1998 Report on Osteoporosis in the European Community. Office for Official Publications of the European Community, Luxembourg City, Luxembourg.
5. National Osteoporosis Foundation 1998 Physicians Guide to Prevention and Treatment of Osteoporosis. Excerpta Medica, Belle Mead, NJ, USA.
6. Hui SL, Slemenda CW, Johnston CC 1988 Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81:1804-1809.
7. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B 2001 Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989-995.
8. Gardsell P, Johnell O, Nilsson BE 1989 Predicting fractures using forearm bone densitometry. Calcif Tissue Int 44:235-242.
9. Lauritzen JB, Schwartz P, McNair P, Lund B, Transbol I 1993 Radial and humeral fractures as predictors of subsequent hip, radial or humeral fractures in women and their seasonal variation. Osteoporos Int 3:133-137.
10. Ross PD, Genant HK, Davis JW, Miller PD, Wasnich RD 1993 Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporos Int 3:120-126.
11. Wasnich RD, Davis JW, Ross PD 1994 Spine fracture risk is predicted by non-spine fractures. Osteoporos Int 4:1-5.
12. Garnero P, Hauser E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breard G, Meunier PJ, Delmas PD 1996 Markers of bone turnover predict hip fractures in elderly women: The EPIDOS prospective study. J Bone Miner Res 11:1531-1538.
13. Hansen M, Overgaard K, Riis B, Christiansen C 1991 Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 303:961-964.
14. Riis B 1995 The role of bone loss. Am J Med 98(Suppl 2A):29-32.
15. Van Staa TP, Leufkens HG, Abenheim L, Zhang B, Cooper C 2000 Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993-1000.
16. Johnell O, De Laet C, Johanssen H, Melton LJ, Eisman J, Reeve J, Tenenhouse A, McCloskey EV, Kanis JA 2002 Oral corticosteroids increase fracture risk independently of BMD. Osteoporos Int 13(Suppl 1):S14.
17. Kanis JA, Johnell O, Oden A, De Laet C, Jonsson B, Dawson A 2002 Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 30:251-258.
18. Looker AC, Orwoll ES, Johnston CC, Lindsay RL, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP 1977 Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res 12:1761-1768.
19. Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A 2000 Risk of hip fracture according to the World Health Organization criteria for osteoporosis and osteopenia. Bone 27:585-590.
20. Kanis JA, Oden A, Johnell O, Jonsson B, De Laet C, Dawson A 2001 The burden of osteoporotic fractures: A method for setting intervention thresholds. Osteoporos Int 12:417-427.
21. Kanis JA 2002 Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929-1936.
22. Kanis JA, Black D, Cooper C, Dargent P, Dawson-Hughes B, De Laet C, Delmas P, Eisman J, Johnell O, Jonsson B, Melton LJ, Oden A, Papapoulos S, Pols H, Rizzoli R, Silman A, Tenenhouse A 2002 A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 13:527-536.
23. Nelson HD, Morris CD, Kraemer DF, Mahon S, Carney N, Nygren PM, Helfand M 2002 Osteoporosis in postmenopausal women: Diagnosis and monitoring. Evidence report/ Technology Assessment, number 28. Agency for Healthcare Research and Quality (AHRQ publication no 01-EO32): Rockville, MD, USA.
24. Nelson HD, Helfand M, Woolf SH, Allan JB 2002 Screening for postmenopausal osteoporosis: A review of the evidence for the US Preventive Services Task Force. Ann Intern Med 137:529-541.
25. US Preventive Services Task Force 2002 Screening for osteoporosis in postmenopausal women: Recommendations and rationale. Ann Intern Med 137:526-528.
26. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Conor E, Musliner TA, Palermo L, Prince R, Rubin SM, Scott JC, Voigt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280:2077-2082.
27. Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321-333.
28. Johnell O, Kanis JA, Black D, Secrest R, Sakar S, Fuerst T, Zhon C, Pavo I 2002 Raloxifene significantly reduces vertebral fracture risk in patients with osteopenia. Osteoporos Int 13(Suppl 3):S69-S70.
29. 3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: Randomised double blind controlled trial. BMJ 326:469-472.
30. Black DM, Thompson D, Quandt S, Palermo L, Ensrud K, Johnell O 2002 Alendronate reduces risk of vertebral fracture in women with BMD T-scores above - 2.5 SD: Results from the Fracture Intervention Trial (FIT). J Bone Miner Res 17:SI;S474.
31. Marcus R, Wang O, Satterwhite J, Mitlack B 2003 The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18:18-23.
32. Miller PD 2003 Editorial. Greater risk, greater benefits - true or false. J Clin Endocrinol Metab 88:538-541.
33. Watts NB, Josse RG, Hamdy RC, Hughes RA, Manhart MD, Barton I, Galligeros D, Felsenberg D 2003 Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 88:542-549.